Other studies [34, 35] have noted that, compared with CD90+ MSCs, CD90- MSCs promote tumor vascularization and immunosuppression, which may explain why there was no significant difference in glioma patient survival according to CD90 expression in our study. Here, THY1 is linked to neoplasm.